Trials / Recruiting
RecruitingNCT07239973
A Study of BGM0504 Tablets in Healthy and Non-diabetic Overweight or Obese Chinese Subjects
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single/Multiple-dose Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of BGM0504 Tablets Orally Administered in Healthy and Non-diabetic Overweight or Obese Chinese Subjects.
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 75 (estimated)
- Sponsor
- BrightGene Bio-Medical Technology Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
A Randomized, Double-Blind, Placebo-Controlled, Single/Multiple-dose Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of BGM0504 Tablets Orally Administered in Healthy and Non-diabetic Overweight or Obese Chinese Subjects.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BGM0504 tablets | Administered p.o. |
| DRUG | Placebo tablets | Administered p.o. |
Timeline
- Start date
- 2025-10-21
- Primary completion
- 2026-03-31
- Completion
- 2026-03-31
- First posted
- 2025-11-20
- Last updated
- 2025-11-20
Locations
1 site across 1 country: China
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07239973. Inclusion in this directory is not an endorsement.